Palisade Bio logo
Palisade Bio
PALI | NASDAQ
Chart Builder DCF Calculator
$1.03
-$0.09 (-8.04%)
At close: Nov 16, 2026, 4:00 PM ET
$1.03
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Palisade Bio Company Profile

Company profile explained

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Key Executives

Name Position
J. D. Finley Chief Executive Officer, Chief Financial Officer & Director
Adarsh Patel Head of Chemistry, Manufacturing & Controls
Daniel J. Larkins Head of Global Regulatory Affairs
Dawn Louro VP & Head of Clinical Operations
James Izanec VP & Head of Clinical Development
Joerg Heyer Head of Translational Science & Medicine
Mitchell Lawrence Jones President & Chief Medical Officer
Ramesh C. Donthamsetty Senior VP of Corporate Development & Investor Relations
Ryker Willie Senior Vice President of Finance & Corporate Controller

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 21, 2026 4 Filing
Oct 21, 2026 3 Filing
Oct 07, 2026 4 Filing
Oct 07, 2026 4 Filing
Oct 05, 2026 4 Filing
Aug 21, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 10, 2026 8-K Current Report
View All SEC Filings ➞
Palisade Bio
Palisade Bio logo
Country United States
IPO Date Mar 30, 2007
Industry Biotechnology
Sector Healthcare
Employees 14
CEO J. D. Finley

Contact Details

4600 South Syracuse Street Denver, California 80237 United States

Stock Details

Ticker Symbol PALI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001357459
CUSIP Number 696389402
ISIN Number US6963894026
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.